TRUFF - Braxia Scientific's Q2 2024: Cash Burn Over But Income Low What's Next For Psychedelics Company? | Benzinga
Ontario-based Canadian psychedelics company Braxia Scientific Corp. (OTC Pink: BRAXF) filed its interim financial statements and management discussion for the three and six months ended Sept. 30, 2023.
Numbers show:
-
Cash of $524,454 (CA$709,681) by Sept. 30, vs. $636,483 by June 30, and $1.08 million by March 31, 2023.
See full Q1 results.
-
Three and six-month revenue of $439,026 and $882,577 vs. $336,439 and $644,971 during the same comparable periods in 2022. Meaning YoY revenue increase of 30.5% and 36.8%, respectively.
-
Three and six-month operating expenses of $294,455 and $949,315 compared to $1.57 million and $2.35 million in the same periods in 2022. This means a major YoY operating expenses decrease of 81.2% and 59.7%, respectively.
-
Six-month net loss of $794,488 as compared to $2.45 million in the same period in 2022, an almost 68% YoY decrease.
See Also: Canada-based psychedelics company Red Light Holland’s (OTCQB: TRUFF)